1798-P: Combined Semaglutide and Sodium–Glucose Cotransporter 2 Inhibitors in Real-World Clinical Practice in China: Scholar Post Hoc Analysis

Introduction and Objective: Combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are increasingly prescribed in China. This post hoc analysis of SCHOLAR (NCT06351748) investigated A1C changes and the safety profile of combined semaglutide (sema)-SGLT2i. Methods: Adults with type 2 diabetes (T2D) in the Tianjin electronic health record database with ≥1 SGLT2i prescription within 6 months of initiating once-weekly subcutaneous sema were included. Participants were grouped according to sema prescription (continuous or not) and by baseline (BL) A1C. Key endpoints: participants prescribed sema-SGLT2i (%); A1C change (BL to month 6); sema-SGLT2i safety profile. Results: In total, 11,361 participants (42.3% of SCHOLAR full analysis set) were prescribed sema-SGLT2i, 3607 (31.7%) of whom were prescribed continuous sema. Overall, mean (SD) BL values: age 57.2 (12.4) yrs; T2D duration 4.6 (3.2) yrs; BMI 26.5 (3.9) kg/m2; A1C 8.04% (1.74). Sema-SGLT2i was associated with a significant A1C reduction (p<0.0001); continuous sema use and BL A1C ≥7% groups had the greatest reduction vs other groups (Figure A). There were no new safety concerns with combination therapy (Figure B). Conclusion: Combined sema-SGLT2i was associated with A1C reductions, with greater reductions in continuous vs non-continuous sema groups, and no new safety concerns. Disclosure S. Wang: None. B. Dong: Employee; Current; Novo Nordisk. Z. Shen: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. L. Chen: Research Support; Current; AstraZeneca, Lilly, Gan & Lee Pharmaceuticals, Novo Nordisk, Sanofi.